CJC-1295 / Ipamorelin — GHRH/GHS Composite
5mg / 5mg Growth Axis Research Blend · 10mg Total
Available Formats
Vial
Lyophilised powder vial containing both compounds at a 1:1 ratio (5mg CJC-1295 No DAC + 5mg Ipamorelin). Full flexibility in reconstitution.
Cartridge (Reusable Pen)
Pre-filled replacement cartridge compatible with standard reusable research pens. Pen sold separately.
Disposable Pen
Fully pre-loaded, self-contained research pen. Ready to use directly from packaging.
Compound Overview
CJC-1295 No DAC (Mod GRF 1-29) is a synthetic analogue of growth hormone-releasing hormone (GHRH), comprising the first 29 amino acids of GHRH with four amino acid substitutions to improve metabolic stability. The “No DAC” designation indicates this variant lacks the Drug Affinity Complex, resulting in a shorter half-life (~30 minutes) compared to the DAC-conjugated form.
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS) that selectively activates the ghrelin/GHS receptor (GHS-R1a). It is characterised by high selectivity for growth hormone release relative to other pituitary hormones, a property that distinguishes it from earlier-generation secretagogues such as GHRP-6 and hexarelin.
The composite format combines both compounds at a 1:1 ratio for use in research protocols investigating synergistic GHRH/GHS receptor co-activation.
Mechanism of Action
CJC-1295 No DAC — GHRH Receptor (GHRH-R): Binds to and activates the GHRH receptor on anterior pituitary somatotroph cells. GHRH-R activation stimulates cAMP/PKA signalling, leading to pulsatile GH gene transcription and secretion in preclinical models.
Ipamorelin — GHS Receptor (GHS-R1a): Activates the growth hormone secretagogue receptor type 1a, a G-protein coupled receptor expressed in the pituitary and hypothalamus. GHS-R1a activation amplifies GH pulse amplitude through a complementary intracellular pathway (PLC/IP3/DAG) distinct from GHRH-R signalling.
In preclinical research, co-administration of GHRH analogues and GH secretagogues has been observed to produce synergistic amplification of GH pulsatility, exceeding the effect of either compound administered alone.
Published Research
- Teichman SL et al. (2006) — Journal of Clinical Endocrinology and Metabolism, 91(3): 799-805. Pharmacokinetic and pharmacodynamic evaluation of CJC-1295 in healthy subjects.
- Raun K et al. (1998) — European Journal of Endocrinology, 139(5): 552-561. Characterisation of Ipamorelin as a selective GH secretagogue.
Note: Citations are provided for reference purposes only. BioCompounds UK does not make therapeutic claims based on published research data.
Structural & Chemical Data
| Compound Class | GHRH analogue + GH secretagogue (composite) |
| Molecular Targets | GHRH-R (CJC-1295), GHS-R1a (Ipamorelin) |
| Purity | >99% verified by HPLC |
| Form | Lyophilised powder (vial) / Pre-filled solution (cartridge & pen) |
| Quantity | 10mg per unit (5mg CJC-1295 + 5mg Ipamorelin) |
| Solubility | Sterile water / PBS |
| Storage (Dry) | -20 C |
| Storage (Reconstituted) | 2-8 C, use within 4 weeks |
Regulatory & Usage Notice
This product is supplied strictly as a research-grade reference compound for in-vitro laboratory investigation only. It is not approved, intended, or marketed for human or veterinary administration, diagnostic purposes, or therapeutic application. Purchasers must be qualified researchers aged 18+ and agree to handle all compounds in accordance with applicable regulations and good laboratory practice (GLP). BioCompounds UK makes no therapeutic claims regarding this or any compound in its catalogue.
By far the best place to get your stuff from posted next day every time I order wouldn’t go anywhere else now
Best provider I have come across, ordering again next week x